Profile data is unavailable for this security.
About the company
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
- Revenue in CHF (TTM)0.00
- Net income in CHF-12.49m
- Incorporated1996
- Employees--
- LocationSpexis AGHegenheimermattweg 125ALLSCHWIL 4123SwitzerlandCHE
- Phone+41 615671600
- Fax+41 615671601
- Websitehttps://spexisbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lipigon Pharmaceuticals AB | 1.37m | -1.02m | 3.46m | -- | -- | 1.45 | -- | 2.52 | -0.3229 | -0.3229 | 0.2543 | 0.225 | 0.7388 | -- | 14.81 | -- | -54.60 | -314.67 | -75.05 | -426.49 | -- | -- | -73.91 | -488.14 | -- | -- | -- | -- | -- | 444.44 | 67.83 | -- | -- | -- |
| Braster SA | 296.46k | -868.73k | 3.68m | 16.00 | -- | -- | -- | 12.42 | -0.2825 | -0.2825 | 0.0561 | -0.1734 | 0.0601 | 0.0769 | 163.38 | -- | -17.61 | -29.23 | -220.50 | -50.27 | 71.16 | 68.77 | -293.04 | -1,435.54 | 0.3061 | -2.59 | 1.62 | -- | 413.76 | 41.35 | 42.87 | -- | -- | -- |
| NextCell Pharma AB | 1.02m | -3.41m | 3.76m | -- | -- | 0.6805 | -- | 3.67 | -1.18 | -1.18 | 0.3555 | 1.92 | 0.124 | 14.66 | 6.80 | -- | -41.28 | -34.92 | -45.63 | -37.06 | 6.61 | -68.21 | -332.90 | -538.60 | 4.97 | -- | 0.00 | -- | 80.96 | 72.85 | -15.21 | -- | -- | -- |
| Sygnis SA | 3.57m | -1.86m | 3.79m | -- | -- | -- | -- | 1.06 | -0.3614 | -0.3614 | 0.6925 | -- | -- | -- | -- | -- | -- | -6.10 | -- | -9.57 | 50.82 | 56.46 | -53.74 | -22.44 | -- | -10.62 | -- | -- | -33.38 | 44.26 | -266.18 | -- | -- | -- |
| Oncozenge AB | 0.00 | -1.33m | 3.82m | -- | -- | 2.44 | -- | -- | -1.36 | -1.36 | 0.00 | 1.59 | 0.00 | -- | -- | -- | -55.57 | -- | -60.45 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 65.91 | -- | -- | -- |
| Veg of Lund AB (publ) | 403.41k | -1.67m | 3.94m | 7.00 | -- | 1.12 | -- | 9.77 | -0.7328 | -0.7328 | 0.1519 | 1.01 | 0.1337 | 13.74 | 14.40 | 688,000.00 | -55.27 | -129.03 | -82.56 | -209.20 | -384.61 | -781.09 | -413.50 | -923.73 | 0.1256 | -12.90 | 0.1405 | -- | 89.57 | 39.87 | 56.02 | -- | -12.47 | -- |
| IntegraGen SA | 12.23m | -121.20k | 3.95m | 57.00 | -- | 2.08 | 49.54 | 0.3231 | -0.0179 | -0.0179 | 1.88 | 0.2887 | 1.24 | 9.09 | 3.09 | 198,274.60 | -1.23 | -4.20 | -4.00 | -9.43 | 64.75 | 64.10 | -0.9913 | -3.67 | 1.23 | -- | 0.418 | -- | 16.27 | 16.08 | -122.78 | -- | -- | -- |
| Spexis AG | 0.00 | -12.49m | 3.98m | -- | -- | 0.1784 | -- | -- | -0.2547 | -0.2547 | 0.00 | 0.3296 | 0.00 | -- | -- | -- | -35.86 | -50.41 | -44.63 | -62.27 | -- | -- | -- | -892.14 | -- | -- | 0.3098 | -- | -- | -- | -56.41 | -- | -62.03 | -- |
| Fusion Antibodies PLC | 1.80m | -3.24m | 4.08m | 50.00 | -- | 1.53 | -- | 2.26 | -0.0861 | -0.0861 | 0.0436 | 0.0245 | 0.5229 | 3.15 | 1.88 | 31,580.00 | -93.94 | -31.29 | -130.56 | -37.72 | -7.41 | 42.58 | -179.67 | -48.25 | 2.32 | -- | 0.0313 | -- | -39.55 | 1.52 | -116.33 | -- | -23.83 | -- |
| Acticor Biotech SA | 0.00 | -18.25m | 4.16m | 24.00 | -- | 9.05 | -- | -- | -1.68 | -1.68 | 0.00 | 0.0298 | 0.00 | -- | -- | 0.00 | -145.59 | -- | -297.22 | -- | -- | -- | -- | -- | -- | -9.32 | 0.9504 | -- | -- | -- | -25.94 | -- | -- | -- |
| Hybrigenics SA | 0.00 | -67.69k | 4.26m | 17.00 | -- | 0.3102 | -- | -- | -0.0003 | -0.0003 | 0.00 | 0.0361 | 0.00 | -- | -- | -- | -0.7067 | -35.48 | -0.877 | -48.94 | -- | -- | -- | -5,115.72 | -- | -- | 0.1032 | -- | 100.00 | -- | 78.83 | -- | -- | -- |
| Pila Pharma AB | 122.55k | -831.78k | 4.29m | 1.00 | -- | 7.68 | -- | 34.97 | -0.5304 | -0.5304 | 0.0767 | 0.28 | 0.1513 | -- | 6.11 | 1,463,020.00 | -102.68 | -108.88 | -122.66 | -121.45 | -127.88 | -42.67 | -678.73 | -1,577.64 | -- | -159.47 | 0.104 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
| Quantum Genomics SA | 9.85k | -3.10m | 4.33m | 3.00 | -- | 10.12 | -- | 439.33 | -0.091 | -0.091 | 0.0003 | 0.0125 | 0.0007 | -- | 0.0016 | 3,353.33 | -23.14 | -60.77 | -95.19 | -102.24 | -14,205.07 | -3,548.91 | -31,520.38 | -3,374.13 | -- | -146.53 | 0.8615 | -- | -98.34 | -- | 87.28 | -- | -- | -- |
| Hellenic Dynamics PLC | -114.15bn | -114.15bn | 4.36m | 25.00 | -- | 4.81 | -- | -- | -- | -- | -- | 0.006 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.3029 | -- | -- | -- | -- | -- | -- | -- |
| Diagonal Bio AB | 1.93k | -978.12k | 4.53m | 4.00 | -- | 0.2468 | -- | 2,349.01 | -0.1982 | -0.1982 | 0.0004 | 0.3221 | 0.0007 | -- | 2.00 | 5,750.00 | -37.35 | -- | -44.49 | -- | -41,604.35 | -- | -50,769.57 | -- | 0.5105 | -104.20 | -- | -- | -88.67 | -- | 27.75 | -- | -- | -- |
| Oxford Cannabinoid Tchnlgs Hldngs PLC | 0.00 | -4.84m | 4.60m | 7.00 | -- | 1.82 | -- | -- | -0.0044 | -0.0044 | 0.00 | 0.002 | 0.00 | -- | -- | 0.00 | -82.98 | -56.41 | -104.70 | -66.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.16 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Spexis AG's reporting currency: Swiss Franc CHF
0.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 405.18k | 0.60% |
| Z�rcher Kantonalbank (Investment Management)as of 29 Feb 2024 | 77.22k | 0.11% |
| UBS Asset Management Switzerland AGas of 02 Apr 2024 | 71.00k | 0.11% |
| Credit Suisse AGas of 31 Jan 2024 | 25.45k | 0.04% |
| Pictet Asset Management SAas of 31 Dec 2023 | 18.33k | 0.03% |
| BlackRock Asset Management Schweiz AGas of 04 Apr 2024 | 18.00k | 0.03% |
| LLB Asset Management AGas of 29 Feb 2024 | 2.35k | 0.00% |
| State Street Global Advisors France SAas of 31 Dec 2023 | 1.50k | 0.00% |
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
